Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04373642 · ClinicalTrials.gov registry record · Phase 2

"QUAD SHOT" Radiotherapy With Pembrolizumab in Patients With Recurrent Head & Neck Cancer

A Phase 2 study of Head and Neck Cancer, sponsored by University of Oklahoma.

Active
Registry status
Phase 2
Development phase
30
Enrollment target
1
Study location

NCT04373642: Active Phase 2 study of Head and Neck Cancer, sponsored by University of Oklahoma.

NCT04373642 is a Phase 2 study of Head and Neck Cancer that is active but no longer recruiting, run by University of Oklahoma. The registered enrollment target is 30 participants, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04373642, a Phase 2 study of Head and Neck Cancer, is active but no longer recruiting, sponsored by University of Oklahoma.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to test the safety of palliative "QUAD SHOT" radiotherapy combined with pembrolizumab and evaluate the effects of the combination treatment patients with recurrent cancer of head and neck.

Conditions Studied

Head and Neck Cancer

Interventions

  • DRUG Pebrolizumab + QUADSHOT Radiotherapy

Study Locations (1)

Oklahoma

  • Stephenson Cancer Center - Oklahoma City

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2020-12-23
Est. Completion 2026-10
Phase Phase 2
University of Oklahoma

358 total trials

What the registry record for NCT04373642 still lists

NCT04373642 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 261-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (89% lower).

The record links to 1 condition, with Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which Pebrolizumab + QUADSHOT Radiotherapy is the first listed.

NCT04373642 reports a single indexed study location in Oklahoma.

Frequently Asked Questions

What is clinical trial NCT04373642 about?

NCT04373642 is a clinical study titled ""QUAD SHOT" Radiotherapy With Pembrolizumab in Patients With Recurrent Head & Neck Cancer". The purpose of this study is to test the safety of palliative "QUAD SHOT" radiotherapy combined with pembrolizumab and evaluate the effects of the combination treatment patients with recurrent cancer of head and neck.

What is the current status of trial NCT04373642?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2020-12-23. Estimated completion is 2026-10.

What conditions does trial NCT04373642 study?

This clinical trial studies the following conditions: Head and Neck Cancer.

What interventions are being tested in trial NCT04373642?

The interventions under investigation include: Pebrolizumab + QUADSHOT Radiotherapy (DRUG).

Who is sponsoring clinical trial NCT04373642?

This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04373642 being conducted?

This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04373642's enrollment target sits among peer trials

30 174th of 250 higher than 66 of 250 other Head and Neck Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Head and Neck Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04373642, the US trial registry maintained by the National Library of Medicine. NCT04373642 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.